{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:15:14Z","timestamp":1789143314415,"version":"build-2803163510"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX24_1852"],"award-info":[{"award-number":["KYCX24_1852"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373183"],"award-info":[{"award-number":["82373183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117231","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T21:31:43Z","timestamp":1786051903000},"page":"117231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CAR-T cell therapy for autoimmune diseases: from immune suppression to immune resetting"],"prefix":"10.1016","volume":"187","author":[{"given":"Mengting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2026.117231_bb0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10391","key":"10.1016\/j.intimp.2026.117231_bb0015","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2026.117231_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103359","article-title":"Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/annrheumdis-2018-214802","article-title":"All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013)","volume":"78","author":"Tselios","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0030","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mayocp.2019.01.002","article-title":"Trends in prevalence of functional disability in rheumatoid arthritis compared with the general population","volume":"94","author":"Myasoedova","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2026.117231_bb0040","article-title":"Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy","volume":"16","author":"Liang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103418","article-title":"When should targeted therapies be used in the treatment of lupus nephritis: early in the disease course or in refractory patients?","volume":"23","author":"Parodis","year":"2024","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2026.117231_bb0050","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.117231_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1647066","article-title":"Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions","volume":"16","author":"Alsayb","year":"2025","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117231_bb0060","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0065","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.intimp.2026.117231_bb0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2020.09.009","article-title":"Leveraging heterogeneity in systemic lupus erythematosus for new therapies","volume":"27","author":"Allen","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.intimp.2026.117231_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101653","article-title":"Cellular and molecular heterogeneity in systemic lupus erythematosus","volume":"58","author":"Fava","year":"2021","journal-title":"Semin. Immunol."},{"issue":"10373","key":"10.1016\/j.intimp.2026.117231_bb0080","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"issue":"Si","key":"10.1016\/j.intimp.2026.117231_bb0085","doi-asserted-by":"crossref","first-page":"Si54","DOI":"10.1093\/rheumatology\/keac363","article-title":"Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort","volume":"62","author":"Hughes","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2026.117231_bb0090","article-title":"B cells in rheumatoid arthritis: pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117231_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cells13090743","article-title":"Clinical phenotypes, serological biomarkers, and synovial features defining seropositive and seronegative rheumatoid arthritis: a literature review","volume":"13","author":"Perera","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2026.117231_bb0105","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"91","key":"10.1016\/j.intimp.2026.117231_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi2848","article-title":"A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response","volume":"9","author":"Wu","year":"2024","journal-title":"Sci. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117231_bb0120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.117231_bb0125","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004727","article-title":"Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel","volume":"10","author":"Szabo","year":"2024","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.intimp.2026.117231_bb0135","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117231_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103621","article-title":"Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial","volume":"90","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.intimp.2026.117231_bb0145","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117231_bb0150","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2026.117231_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.706951","article-title":"Pleiotropic effects of glucocorticoids on the immune system in circadian rhythm and stress","volume":"12","author":"Shimba","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117231_bb0160","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0170","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2026.117231_bb0175","article-title":"Mycophenolate mofetil: an update on its mechanism of action and effect on lymphoid tissue","volume":"15","author":"Krawczyk","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jca.21953","article-title":"Immunoadsorption and plasma exchange-efficient treatment options for neurological autoimmune diseases","volume":"37","author":"Boedecker","year":"2022","journal-title":"J. Clin. Apher."},{"issue":"6382","key":"10.1016\/j.intimp.2026.117231_bb0190","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.intimp.2026.117231_bb0195","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0200","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2026.117231_bb0205","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0215","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41598-021-04296-3","article-title":"The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r\/r B-ALL patients","volume":"12","author":"Li","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.117231_bb0220","article-title":"CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch","volume":"17","author":"Huang","year":"2026","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117231_bb0225","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0230","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10416","key":"10.1016\/j.intimp.2026.117231_bb0240","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.intimp.2026.117231_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70298","article-title":"Chimeric antigen receptor T-cell therapy and autoimmune diseases in the nervous system","volume":"13","author":"Yao","year":"2025","journal-title":"Immun. Inflamm. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2026.117231_bb0250","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"18","key":"10.1016\/j.intimp.2026.117231_bb0255","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1182\/bloodadvances.2024012909","article-title":"CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD","volume":"8","author":"Verma","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117231_bb0260","article-title":"Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses","author":"Zhang","year":"2026","journal-title":"Nat. Commun."},{"issue":"10522","key":"10.1016\/j.intimp.2026.117231_bb0265","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","article-title":"Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China","volume":"406","author":"Gao","year":"2026","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2026.117231_bb0270","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117231_bb0280","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0285","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.intimp.2026.117231_bb0290","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2026.117231_bb0295","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for Cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"3","key":"10.1016\/j.intimp.2026.117231_bb0300","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.117231_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"11","key":"10.1016\/j.intimp.2026.117231_bb0310","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.117231_bb0315","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.intimp.2026.117231_bb0320","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"76","key":"10.1016\/j.intimp.2026.117231_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo0777","article-title":"Antigen-specific depletion of CD4(+) T cells by CAR T cells reveals distinct roles of higher- and lower-affinity TCRs during autoimmunity","volume":"7","author":"Yi","year":"2022","journal-title":"Sci. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117231_bb0330","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0335","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2026.117231_bb0340","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150985","article-title":"Positive and negative selection shape the human naive B cell repertoire","volume":"132","author":"Chen","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.117231_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.991840","article-title":"B cell-T cell interplay in immune regulation: a focus on follicular regulatory T and regulatory B cell functions","volume":"10","author":"Tan","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2026.117231_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.677036","article-title":"How does B cell antigen presentation affect memory CD4 T cell differentiation and longevity?","volume":"12","author":"Welsh","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117231_bb0355","article-title":"The influence of B cell depletion therapy on naturally acquired immunity to Streptococcus pneumoniae","volume":"11","author":"Ercoli","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0360","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0365","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41573-025-01349-4","article-title":"Roads and detours for CAR T cell therapy in autoimmune diseases","volume":"25","author":"Avouac","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"18","key":"10.1016\/j.intimp.2026.117231_bb0370","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2026.117231_bb0375","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0380","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117231_bb0385","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/bloodadvances.2021006112","article-title":"Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy","volume":"6","author":"Dahiya","year":"2022","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0390","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.intimp.2026.117231_bb0395","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.intimp.2026.117231_bb0400","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0405","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.117231_bb0410","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","article-title":"BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis","volume":"84","author":"Hu","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.intimp.2026.117231_bb0420","article-title":"CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0425","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.intimp.2026.117231_bb0430","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146743","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2026.117231_bb0435","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-71473-1","article-title":"Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response","author":"Ozog","year":"2026","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2026.117231_bb0440","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jtct.2025.02.019","article-title":"T cell immune response to influenza vaccination when administered prior to and following autologous chimeric antigen receptor-modified T cell therapy","volume":"31","author":"Kinoshita","year":"2025","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.intimp.2026.117231_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical disease activity and flare in SLE: current concepts and novel biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0450","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13075-017-1442-6","article-title":"Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review","volume":"19","author":"Gensous","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2026.117231_bb0455","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117231_bb0460","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/rheumatology\/kead231","article-title":"SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus-an analysis of anti-double-stranded DNA monitoring","volume":"63","author":"Yeo","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3s","key":"10.1016\/j.intimp.2026.117231_bb0465","first-page":"S71","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group","year":"2024","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0470","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004387","article-title":"Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data","volume":"10","author":"Duarte","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.intimp.2026.117231_bb0475","article-title":"The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis","volume":"5","author":"Orr","year":"2018","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.intimp.2026.117231_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1757895","article-title":"Interferon levels and interferon-stimulated gene expression identify patient subsets with distinct clinical and immunological characteristics in systemic lupus erythematosus","volume":"17","author":"Khatri","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0485","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13075-025-03560-5","article-title":"Bioinformatic analysis and experimental verification reveal expansion of monocyte subsets with an interferon signature in systemic lupus erythematosus patients","volume":"27","author":"Zhang","year":"2025","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2026.117231_bb0490","first-page":"220","article-title":"Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases","volume":"78","author":"Dik","year":"2020","journal-title":"Neth. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0495","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001745","article-title":"Trajectories of long-term eGFR and proteinuria in lupus nephritis: a real-world biopsy-proven cohort study","volume":"13","author":"Ning","year":"2026","journal-title":"Lupus Sci Med."},{"issue":"482","key":"10.1016\/j.intimp.2026.117231_bb0500","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.intimp.2026.117231_bb0505","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0510","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2026.117231_bb0515","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0520","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2026.117231_bb0525","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr. Dir. Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0530","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117231_bb0535","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.117231_bb0540","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7388.1","article-title":"Can follicular helper T cells be targeted to improve vaccine efficacy?","volume":"5","author":"Linterman","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.intimp.2026.117231_bb0545","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","article-title":"Follicular helper T cells","volume":"34","author":"Vinuesa","year":"2016","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117231_bb0550","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"D\u00f6rner","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.117231_bb0555","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117231_bb0560","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117231_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1539773","article-title":"Decoding plasma cell maturation dynamics with BCMA","volume":"16","author":"Schulz","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0570","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12016-025-09114-6","article-title":"Chimeric antigen receptor T cell therapy in systemic lupus erythematosus: mechanisms, clinical advances, and future directions a comprehensive review","volume":"68","author":"Matarneh","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117231_bb0575","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat. Med."},{"issue":"47","key":"10.1016\/j.intimp.2026.117231_bb0580","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000045698","article-title":"Advances and prospects of CAR-T cell therapy in autoimmune disease treatment","volume":"104","author":"Wang","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0585","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-026-01779-6","article-title":"BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial","volume":"19","author":"Hong","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117231_bb0590","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2023.06.005","article-title":"Targeting plasma cells in systemic autoimmune rheumatic diseases - promises and pitfalls","volume":"260","author":"Steinmetz","year":"2023","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2026.117231_bb0595","article-title":"Case report: remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117231_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100749","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"6","author":"Wang","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0605","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-025-01321-w","article-title":"Humoral vaccine responses following chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"15","author":"Einarsdottir","year":"2025","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.intimp.2026.117231_bb0610","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41423-018-0198-5","article-title":"CD70 defines a subset of proinflammatory and CNS-pathogenic T(H)1\/T(H)17 lymphocytes and is overexpressed in multiple sclerosis","volume":"16","author":"Dhaeze","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2026.117231_bb0615","article-title":"CD70 as a target in cancer immunotherapy: advances, challenges, and future directions","volume":"15","author":"Wu","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117231_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715909","article-title":"Targeting the CD27-CD70 pathway to improve outcomes in both checkpoint immunotherapy and allogeneic hematopoietic cell transplantation","volume":"12","author":"Lutfi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117231_bb0625","article-title":"A mechanistic, functional, and clinical perspective on targeting CD70 in cancer","volume":"611","author":"Kumar","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0630","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2026.117231_bb0635","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/rheumatology\/keu171","article-title":"CD70-expressing CD4 T cells produce IFN-\u03b3 and IL-17 in rheumatoid arthritis","volume":"53","author":"Park","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2026.117231_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103137","article-title":"Associations between CD70 methylation of T cell DNA and age in adults with systemic lupus erythematosus and population controls: the Michigan Lupus Epidemiology & Surveillance (MILES) program","volume":"142","author":"Somers","year":"2024","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0645","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s42003-020-1097-8","article-title":"CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells","volume":"3","author":"Arroyo Hornero","year":"2020","journal-title":"Commun. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117231_bb0650","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00109-021-02116-9","article-title":"CD27 expression on Treg cells limits immune responses against tumors","volume":"100","author":"Muth","year":"2022","journal-title":"J. Mol. Med. (Berl)"},{"issue":"6788","key":"10.1016\/j.intimp.2026.117231_bb0655","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1126\/science.adv7378","article-title":"Sensitive CAR T cells redefine targetable CD70 expression in solid tumors","volume":"391","author":"Hanina","year":"2026","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0660","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-026-02076-9","article-title":"CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties","volume":"26","author":"Cheng","year":"2026","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0665","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/bloodadvances.2025018076","article-title":"Blood tests to predict CAR T-cell toxicity and efficacy","volume":"10","author":"Weinkove","year":"2026","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117231_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117231_bb0675","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.intimp.2026.117231_bb0680","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117231_bb0685","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0690","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"10.1016\/j.intimp.2026.117231_bb0695","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.intimp.2026.117231_bb0700","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.fsi.2020.11.021","article-title":"Surviving under pollution stress: antibacterial and antifungal activities of the oyster species (Magallana bilineata and Magallana cuttackensis)","volume":"108","author":"Hussain Chan","year":"2021","journal-title":"Fish Shellfish Immunol."},{"key":"10.1016\/j.intimp.2026.117231_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcab.2021.102097","article-title":"Isolation and characterization of small colony variants of Staphylococcus aureus in various food samples","volume":"35","author":"Hussain Chan","year":"2021","journal-title":"Biocatal. Agric. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117231_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.microb.2025.100365","article-title":"Antibacterial and antibiofilm properties of lysozyme extracted from Catostylus perezi, an invaluable jellyfish bloom","volume":"7","author":"Naveed","year":"2025","journal-title":"Microbe"},{"issue":"4","key":"10.1016\/j.intimp.2026.117231_bb0715","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005866","article-title":"Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner\/disciplinary working group perspective","volume":"11","author":"Hsieh","year":"2025","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.intimp.2026.117231_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape-lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"7","key":"10.1016\/j.intimp.2026.117231_bb0725","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117231_bb0730","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2026.117231_bb0735","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","article-title":"T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities","volume":"34","author":"Baeuerle","year":"2022","journal-title":"Curr. Opin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117231_bb0740","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3324\/haematol.2023.283780","article-title":"Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed\/refractory acute lymphoblastic B-lineage leukemia in children and young adults","volume":"109","author":"Feuchtinger","year":"2024","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.intimp.2026.117231_bb0745","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:03:35Z","timestamp":1789142615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926010775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":149,"alternative-id":["S1567576926010775"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117231","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy for autoimmune diseases: from immune suppression to immune resetting","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117231"}}